Case Report of a Patient Undergoing Peritoneal Dialysis with Encapsulating Peritoneal Sclerosis Superimposed With Calciphylaxis

INTRODUCTION: Encapsulating peritoneal sclerosis (EPS) is a rare but devastating complication of peritoneal dialysis (PD). Tamoxifen has been generally well-tolerated, even without randomized controlled trials. CASE PRESENTATION: Herein, we report a case of a patient undergoing 12 years of PD who de...

Descripción completa

Detalles Bibliográficos
Autores principales: Li Tsai, Jun, Ju Wu, Ming, Hsu Chen, Cheng, Feng Tsai, Shang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065917/
https://www.ncbi.nlm.nih.gov/pubmed/27781116
http://dx.doi.org/10.5812/ircmj.30913
Descripción
Sumario:INTRODUCTION: Encapsulating peritoneal sclerosis (EPS) is a rare but devastating complication of peritoneal dialysis (PD). Tamoxifen has been generally well-tolerated, even without randomized controlled trials. CASE PRESENTATION: Herein, we report a case of a patient undergoing 12 years of PD who developed EPS and calciphylaxis simultaneously. We also provide a comprehensive discussion about the association between EPS and calciphylaxis. Moreover, although tamoxifen is used in EPS due to its inhibition of fibroblast-transforming growth factor beta (TGFβ) production, it may worsen the calciphylaxis due to a hypercoagulable state. CONCLUSIONS: We suggest avoiding the use of tamoxifen for EPS in patients with superimposed calciphylaxis.

Ejemplares similares